Anti Amyloid Leqembi denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied Leqembi for Medical Necessity — and Why You Can Appeal

Medical-necessity denials for Leqembi (lecanemab) typically occur when UHC determines the patient has not met one or more clinical eligibility criteria set out in its coverage policy — such as documentation of disease stage, amyloid confirmation, cognitive status assessment, or absence of conditions the policy treats as exclusionary. These denials are not final: they are reviewable, and many are overturned when complete clinical documentation is submitted.

## Why This Denial Is Appealable

Under ACA §2719, ERISA §503, and applicable state insurance law, UHC must provide a full internal appeal followed by independent external review. You generally have 180 days from the denial notice to initiate an internal appeal. External review, conducted by independent board-certified clinicians, must typically be completed within 45 days (or 72 hours for expedited cases). External review is especially valuable for medical-necessity denials because the reviewer is a specialist — not the insurer — and must apply accepted clinical standards.

## What to Gather

• Diagnosis confirmation: Formal neuropsychological testing, cognitive assessments, and a clinical diagnosis of early Alzheimer's disease from the treating neurologist or specialist.
• Amyloid confirmation: PET imaging report or CSF biomarker results confirming amyloid pathology — this is a core criterion under both the FDA label and UHC's policy.
• Disease stage documentation: Chart notes, functional assessments, and staging records showing the patient falls within the early-stage population for which the drug is approved.
• Prior treatment history: Dates and outcomes of prior therapies tried, with reasons any required steps were completed or not applicable.
• Prescriber medical-necessity letter: A detailed letter from the treating specialist mapping each policy criterion to the specific clinical evidence in the patient's chart, citing the FDA label for eligibility parameters.
• Safety monitoring plan: MRI surveillance records and REMS enrollment, showing the prescriber is following the label's safety requirements.

## Criteria-Mapping Approach

Obtain the exact text of UHC's current Leqembi coverage policy. List every criterion. For each, identify the specific document in the chart that satisfies it — do not leave any criterion unaddressed. Where a criterion involves a numeric threshold (such as a cognitive score range or a lab value), obtain the exact threshold from the policy and the FDA prescribing information; do not rely on memory or secondary sources. The prescriber's letter should walk through this mapping explicitly, criterion by criterion.